OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 okt 2008 - 23:17
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces exclusive license and manufacturing agreement for Locteron with Biolex allowing for revenues in excess of 100 million euro
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery company, announces today that it has signed an exclusive license and product acquisition agreement to license its share of the commercial rights to its lead product Locteron® to co-development partner Biolex Therapeutics. OctoPlus will remain a partner in the process development and manufacture of Locteron, but without having to make the investments for the upcoming late-stage clinical program. The proceeds of the agreement include among others upfront and milestone payments that amount to a total of US$ 149 million (€ 108 million) in the coming years, and royalties on future Locteron sales. The upfront fee and short-term milestone payments comprise the first significant revenues that OctoPlus generates from the commercialisation of its drug delivery technology PolyActive®. In addition to the cash payments under the agreement, OctoPlus will receive an equity stake in Biolex of up to 3.0%.
Datum laatste update: 18 december 2025